As of 2025-05-16, the Fair Value of BioLine RX Ltd (BLRX.TA) is -2.07 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 1.90 USD, the upside of BioLine RX Ltd is -208.69%.
With the market price of 1.90 USD and our fair value calculation, BioLine RX Ltd (BLRX.TA) is not a good investment. Investing in BLRX.TA stocks now will result in a potential loss of 208.69%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -30.02 | -27.05 | -24.95 | -60.61 | -9.22 | -30.37 |
| YoY growth | -17.98% | 9.88% | 7.77% | -142.93% | 84.79% | -11.69% |
| Market Cap (mil) | 42.42 |
| P/E | |
| Forward P/E |
| EPS | -0.41 |
| Avg earnings growth rate | -11.69% |
| TTM earnings | -9.22 |